Funding for this research was provided by:
Canadian Institutes of Health Research (363926)
Weston Brain Institute
Received: 17 May 2018
Accepted: 3 September 2018
First Online: 27 September 2018
Ethics approval and consent to participate
: This study has received a no objection letter from Health Canada and investigational new drug approval from the FDA. Ethics approvals will be obtained at each participating site.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.